Treatment of myelofibrosis with refractory anemia with luspatercept: a multicenter Chinese study
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05847-0 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, 2024. Verfasst von Leyu Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Peking Union Medical College Hospital, Chinese Academe of Medical Science and Peking Union Medical College, Beijing, 100730…. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Recombinant Fusion Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Myelofibrosis is a rare and often fatal hematological neoplasm, and the treatment of myelofibrosis-associated anemia remains suboptimal, with no improved therapies. Luspatercept was shown to display some efficacy in a phase 2 clinical trial for Myelofibrosis with anemia, yet relevant research are limited. Threrfore, data from patients diagnosed with refractory anemic primary or post-essential thrombocythemia/polycythemia vera myelofibrosis, who were treated with luspatercept for at least 9 weeks, were retrospectively collected. Eighteen patients with myelofibrosis treated with luspatercept were enrolled. Median age was 68 years (range, 44-80 years), and 27.8% were males. Ten (55.6%) were transfusion-dependent. Ten (55.6%) were Dynamic International Prognostic Scoring System intermediate-1, and eight (44.4%) were intermediate-2. The median follow-up was 7 (4-16) months. Erythroid response occurred in eight patients (44.4%) at week 12, four patients (30.8%) at week 24, and nine (50%) at the end of follow-up. Patients who were transfusion-dependent and not transfusion-dependent had similar HI-E responses, at different time points (P > 0.05). Patients had a significantly higher hemoglobin level at 12 weeks, 24 weeks, and at the end of follow-up, than at baseline (P = 0.001, P = 0.021, and P = 0.005, respectively). Treatment-related adverse events occurred in five (16.7%) patients, with no serious adverse events. Two (11.1%) patients relapsed at weeks 15 and 31. One patient progressed to acute myeloid leukemia. No patients had died by the end of follow-up. Luspatercept induced a good response in patients with anemic myelofibrosis, with a low relapse rate and good tolerance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Peking Union Medical College Hospital, Chinese Academe of Medical Science and Peking Union Medical College, Beijing, 100730, China.
- State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sc…
- Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China.
- Department of Hematology, Yantai Yuhuangding Hospital, Yantai, China.
- Department of Hematology, Huizhou First People's Hospital, Huzhou, China.
- Department of Hematology, People's hospital of Zhengzhou, Zhengzhou, China.
Zitieren
APA
Wang, L., Fang, L., Shi, H., Liu, Y., Long, C., Guo, S., Yang, X., Hu, Q., Liu, Z., Yang, C., Chen, M., & Han, B. (2024). Treatment of myelofibrosis with refractory anemia with luspatercept: a multicenter Chinese study. Annals of Hematology. https://doi.org/10.1007/s00277-024-05847-0
Vancouver
Wang L, Fang L, Shi H, Liu Y, Long C, Guo S, et al. Treatment of myelofibrosis with refractory anemia with luspatercept: a multicenter Chinese study. Annals of Hematology. 2024. doi:10.1007/s00277-024-05847-0
BibTeX
@article{Wang2024,
author = {Wang, Leyu and Fang, Liwei and Shi, Hongxia and Liu, Yinghui and Long, Chan and Guo, Shuxia and Yang, Xiuli and Hu, Qinglin and Liu, Ziwei and Yang, Chen and Chen, Miao and Han, Bing},
title = {Treatment of myelofibrosis with refractory anemia with luspatercept: a multicenter Chinese study},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05847-0}
}
EUVIMED